Novo Nordisk’s Earnings Reckoning: Options Traders Price In a Rare Double-Digit Swing
For a company that spent the better part of a year selling investors on a diversification story, Novo…
Novo Nordisk’s Rally Meets a Revenue Reckoning: Buyback Momentum Clashes with 2026 Guidance
Novo Nordisk has staged a striking recovery over the past month, with the stock climbing 17% even as…
Novo Nordisk’s Summer of Reckoning: Prescription Dominance Meets Pipeline Verdict
Novo Nordisk’s oral Wegovy prescriptions outpace Eli Lilly’s Foundayo 2.4x, yet shares are down 45% from highs. Upcoming…
Novo Nordisk’s Pipeline Push and Buyback Blitz Face a Reckoning at Q1 Earnings
Novo Nordisk faces a pivotal Q1 earnings test amid share buybacks, pipeline diversification beyond semaglutid, and cautious analyst…